

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Health Technology Evaluation**

**Equality impact assessment – Scoping**

**Pegzilarginase for treating arginase-1 deficiency [ID4029]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- |   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

During consultation it was noted that the scope should take into account the ethnicity of the UK patient population with arginase deficiency and the economic and quality of life impact of being a patient or carer of a patient with intellectual and physical disabilities.
--

- |   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

This issue will be taken into account in the committee's decision making.
---

- |  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No
----

- |  |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made? |
|--|

No

**Approved by Associate Director (name):** ...Richard Diaz.....

**Date:** 16/01/2024